AGRX Agile Therapeutics Inc.

2.06
+0.03  (+1%)
Previous Close 2.03
Open 2.02
Price To Book 3.82
Market Cap 122,162,380
Shares 59,302,126
Volume 1,882,662
Short Ratio
Av. Daily Volume 6,570,301
Stock charts supplied by TradingView

NewsSee all news

  1. Agile Therapeutics Announces FDA Extension of Twirla® NDA Review Period

    PRINCETON, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription

  2. Agile Therapeutics Announces Favorable Outcome of FDA Advisory Committee Meeting for its Investigational Transdermal Contraceptive Patch, Twirla® (AG200-15)

    Committee Votes 14 to 1, with 1 Abstention, in Favor of Approval PRINCETON, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, announced a positive outcome

  3. Agile Therapeutics to Present at Upcoming Investor Conferences

    PRINCETON, N.J., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari, will present at

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRLs issued 2013 and 2017. New PDUFA extended by three months to February 16, 2020. Advisory Committee Meeting October 30, 2019 voted 14 to 1 in favor.
Twirla
Contraceptive patch

Latest News

  1. Agile Therapeutics Announces FDA Extension of Twirla® NDA Review Period

    PRINCETON, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription

  2. Agile Therapeutics Announces Favorable Outcome of FDA Advisory Committee Meeting for its Investigational Transdermal Contraceptive Patch, Twirla® (AG200-15)

    Committee Votes 14 to 1, with 1 Abstention, in Favor of Approval PRINCETON, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, announced a positive outcome

  3. Agile Therapeutics to Present at Upcoming Investor Conferences

    PRINCETON, N.J., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari, will present at